Silencing of tissue factor by antisense deoxyoligonucleotide prevents monocrotaline/LPS renal injury in mice

Mohamed Sadek Abdel-Bakky1, Mohamed A Hammad, Larry A Walker

  • 1National Center For Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA.

Archives of Toxicology
|February 18, 2011
PubMed

Insights

Monocrotaline (MCT) and lipopolysaccharide (LPS) co-treatment causes kidney damage by increasing tissue factor (TF). Blocking TF with TF antisense oligonucleotide (TF-AS) prevents this renal toxicity and improves survival.

Area of Science:

  • Nephrology
  • Toxicology
  • Hematology

Background:

  • Tissue factor (TF) is implicated in monocrotaline (MCT)/lipopolysaccharide (LPS) induced liver injury.
  • The role of TF in MCT/LPS-induced kidney toxicity remains uninvestigated.

Purpose of the Study:

  • To investigate the potential renal toxicity of MCT/LPS co-treatment.
  • To determine the involvement of TF in MCT/LPS-induced renal toxicity.

Main Methods:

  • Mice were co-treated with MCT and LPS.
  • TF was blocked using TF antisense oligonucleotide (TF-AS).
  • Renal function markers (BUN, creatinine), fibrin deposition, tubular necrosis, and plasma TF levels were assessed.

Main Results:

  • MCT/LPS co-treatment led to elevated BUN and creatinine, tubular necrosis, and increased plasma TF levels.
  • TF-AS administration prevented these adverse effects, including fibrin deposition and necrosis.
  • TF-AS treatment normalized proinflammatory markers and improved animal survival.

Conclusions:

  • MCT/LPS co-treatment induces significant renal toxicity.
  • TF plays a crucial role in mediating this renal damage.
  • TF blockade is a potential therapeutic strategy to prevent MCT/LPS-induced nephrotoxicity.

Related Concept Videos